<?xml version='1.0' encoding='utf-8'?>
<document id="16182761"><sentence text="Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation." /><sentence text="Pharmacological interactions between protease inhibitors and tacrolimus require careful monitoring to prevent toxicity in the posttransplantation period" /><sentence text=" A 42-year-old man with human immunodeficiency virus (HIV) infection and end-stage liver disease due to hepatitis C virus (HCV) received an orthotopic liver transplant" /><sentence text=" At the time of surgery the patient was on triple antiretroviral therapy (tenofovir, lamivudine, and lopinavir/ritonavir) with a stable CD4(+) count (&gt;500 cells/mm(3)) and HIV-1 RNA (&lt;50 copies/mL)"><entity charOffset="74-83" id="DDI-PubMed.16182761.s4.e0" text="tenofovir" /><entity charOffset="85-95" id="DDI-PubMed.16182761.s4.e1" text="lamivudine" /><entity charOffset="101-110" id="DDI-PubMed.16182761.s4.e2" text="lopinavir" /><entity charOffset="111-120" id="DDI-PubMed.16182761.s4.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e0" e2="DDI-PubMed.16182761.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e0" e2="DDI-PubMed.16182761.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e0" e2="DDI-PubMed.16182761.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e0" e2="DDI-PubMed.16182761.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e1" e2="DDI-PubMed.16182761.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e1" e2="DDI-PubMed.16182761.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e1" e2="DDI-PubMed.16182761.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e2" e2="DDI-PubMed.16182761.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16182761.s4.e2" e2="DDI-PubMed.16182761.s4.e3" /></sentence><sentence text=" Immunosuppression was maintained with tacrolimus (0"><entity charOffset="39-49" id="DDI-PubMed.16182761.s5.e0" text="tacrolimus" /></sentence><sentence text="5 mg at a single dose once per week)" /><sentence text=" One month after surgery HCV recurrence was documented" /><sentence text=" Pharmacokinetic evaluation of lopinavir/ritonavir showed a rapid increase in the area under the curve"><entity charOffset="31-40" id="DDI-PubMed.16182761.s8.e0" text="lopinavir" /><entity charOffset="41-50" id="DDI-PubMed.16182761.s8.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16182761.s8.e0" e2="DDI-PubMed.16182761.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16182761.s8.e0" e2="DDI-PubMed.16182761.s8.e1" /></sentence><sentence text=" Drug concentrations returned to normal levels, with reduction in liver enzymes" /><sentence text=" At the same time, tacrolimus dosages were reduced to a maintenance dose of 0"><entity charOffset="19-29" id="DDI-PubMed.16182761.s10.e0" text="tacrolimus" /></sentence><sentence text="5 mg every 2 weeks" /><sentence text=" The patient, at 17 months postoperatively, is alive in good health with normal liver function and HCV RNA load levels" /><sentence text=" This is the first case in which a profound change in the pharmacokinetics of a protease inhibitor caused by a drug-drug interaction was observed during transient liver damage" /><sentence text=" Because this clinical event is particularly common in HIV-infected patients, our findings suggest that therapeutic drug monitoring should be performed to determine the impact of potential drug interactions in the early posttransplantation period, at the time of resumption of therapy or introduction of new anti-retroviral therapy and during HCV recurrence in order to optimize both tacrolimus and protease inhibitor treatment" /><sentence text="" /></document>